Article info
PDFRheumatoid arthritis
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy
- Correspondence to Mary Safy-Khan, Rheumatology and Clinical Immunology, UMC Utrecht, 3584 CX Utrecht, The Netherlands; marysafy{at}hotmail.com
Citation
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy
Publication history
- Received November 19, 2019
- Revised January 13, 2020
- Accepted January 16, 2020
- First published February 7, 2020.
Online issue publication
May 13, 2021
Article Versions
- Previous version (12 May 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.